Bli medlem
Bli medlem

Du är här

2016-05-18

Immunicum AB: Information from the Extraordinary General Meeting of IMMUNICUM Aktiebolag (publ)

At the Extraordinary General Meeting (the "EGM") in IMMUNICUM Aktiebolag
(publ) on 18 May 2016, the shareholders adopted the resolutions summarized
below:

The EGM resolved to carry out a rights issue of shares with preferential
rights for shareholders in accordance with the proposal of the Board of
Directors. The EGM also resolved to authorize the Board of Directors to, in
the event the rights issue is oversubscribed, resolve on a rights issue of
additional shares (overallotment option) in accordance with the proposal of
the Board of Directors. For more information about the planned capital
raising, please refer to the press release published on 25 April 2016.

The EGM further resolved to authorize the Board of Directors, on one or
several occasions during the period until the next AGM, with or without
deviation from the shareholders' preferential rights, to resolve on a rights
issue of not more than 5 040 000 shares.

The EGM finally resolved to adopt guidelines for executive remuneration in
accordance with the proposal of the Board of Directors.

For further information, please visitwww.immunicum.com.

Jamal El-Mosleh, CEO, Immunicum
Phone: +46 (0) 31 41 50 52
jamal.el-mosleh@immunicum.com

The company's Certified Adviser is Redeye AB
Phone: +46 (0) 8 545 013 31.www.redeye.se

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire

HUG#2013299

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.